Thought Leadership
When it comes to thought leadership and staying informed, we’ve got you covered. See below for recent articles, webinars, and downloadable resources available.
Want updates like these sent directly to your inbox?
On Friday July 7th, 2023, CMS released a proposed rule outlining a plan to correct and reverse the 340B payment cuts from calendar years (CY) 2018 through 2022. This proposed rule is in response to last years Supreme Court ruling that CMS lacked authority to reduce reimbursement for drugs to average sale price (ASP) minus […]
Great news for 340B hospitals impacted by the reimbursement reductions initiated by the Center for Medicare and Medicaid Services (CMS) on January 1, 2018. Recently, CMS announced that the 2023 Medicare outpatient payment rates will be restored to rates prior to 2018 for affected hospitals. After many legal debates, court filings, and outcry from hospitals […]
In June, the Supreme Court gave hospitals participating in the 340B Drug Pricing Program a convincing victory ruling unanimously that the U.S. Center for Medicare & Medicaid Services (CMS) should not have reduced reimbursement for covered outpatient prescription drugs purchased by those hospitals. 340B Hospitals Challenge Payment Rates Hospitals challenged the 2018 and 2019 payment […]
Great news for 340B Hospitals affected by COVID-19. On March 15, 2022, President Biden signed into law the $1.5 trillion Consolidated Appropriations Acts, 2022. This bill allows Hospitals that have lost eligibility due to a decrease in their Medicare disproportionate share (DSH) percentage as a result of the COVID-19 public health emergency to regain access […]
The 340B Program has seen a lot of changes in 2021. Join Blue & Co.’s Apexus Advanced 340B Experts for a webinar on Thursday, July 15 at 12:00 p.m. In this webinar, Jason Prokopik and Chad Downing will be covering some of the current 340B trends and provide updates from recent HRSA Audits that may […]
After months of pharmaceutical manufacturers placing restrictions on the 340B Program to both contract pharmacies and covered entities, HRSA sent letters to six pharmaceutical manufacturers stating they violated the 340B Statute. The HRSA Acting Administrator declared these pharmaceutical manufacturers violated the 340B statue by placing restrictions on the 340B Program pricing at both contract pharmacy […]
Over the past year, there have been many changes within the 340B Program. Join Jason Prokopik from Blue & Co., LLC and Wes Butler from Barnett Benvenuti & Butler on Tuesday, February 9 from noon to 1 p.m. EST as they discuss how the recent political changes could impact the 340B Program and what it […]
On December 27, 2020, President Trump signed into law the Consolidated Appropriations Act (CAA), 2021. Included in this bill are comprehensive Rural Health Clinic reimbursement changes and provide possible new opportunities for both RHCs and hospitals. Rural Health Clinic Medicare Rates The most significant change included in the CAA was made to the RHC Medicare rates. […]
Blue & Co., LLC is excited to announce it has recently expanded its pharmacy and 340B expertise to meet and exceed the needs of its clients. With the addition of multiple pharmacy staff members in 2020, Blue is positioned to provide a wide array of pharmacy consulting services to healthcare organizations looking for guidance. About […]
The 2021 Grantee 340B Recertification period for Consolidated Health Centers, Federal Qualified Health Center Look-Alikes, Ryan White, Comprehensive Hemophilia Treatment Centers, Native Hawaiian, Black Lung Programs, Urban Indian, and Tribal Compact 638 will be February 1 – March 1, 2021. A separate email will be sent out by HRSA with all of the information required […]
With current attacks on the 340B Program by some pharmaceutical manufacturers and other challenges affecting patients in need of prescription drugs, is it time for your Hospital or Health Center to consider a retail pharmacy strategy of its own? Some Hospitals and Health Centers own retail pharmacies, but opportunity still exists to improve the patient […]
340B covered entities have likely felt bombarded during the last few weeks with various letters from manufacturers, word of additional cuts in Medicare part B drug reimbursement for some hospitals, and an executive order about insulin and epi-pens for community health centers. Advocacy groups, including 340B Health, the National Association of Chain Drugstores, the American […]
AstraZeneca distributed letters recently that as of October 1, 2020, 340B pricing will be available only through “a single contract pharmacy for those covered entities that do not maintain their own on-site dispensing pharmacies.” Eli Lilly had previously stated it would provide Cialis at 340B pricing to only one contract pharmacy location for each entity. […]
In 2018, the Center for Medicare & Medicaid Services (CMS) implemented a change in reimbursement for DSHs, RRCs, and non-rural SCHs for Medicare Part B drugs obtained through the 340B Program, adjusting reimbursement amounts based on a value of Average Sales Price (ASP) – 22.5% from the previous value of ASP + 6%. This was […]
The Health Resources and Services Administration has set the annual recertification of eligibility for 340B drug discounts for hospitals to begin August 17, 2020 and end September 14, 2020. Mandatory Requirement Hospitals must complete their recertification through the Office of Pharmacy Affairs Information System (OPAIS). The Authorizing Official and Primary Contact must create their own […]
Webinars
On Friday July 7th, 2023, CMS released a proposed rule outlining a plan to correct and reverse the 340B payment cuts from calendar years (CY) 2018 through 2022. This proposed rule is in response to last years Supreme Court ruling that CMS lacked authority to reduce reimbursement for drugs to average sale price (ASP) minus […]
Great news for 340B hospitals impacted by the reimbursement reductions initiated by the Center for Medicare and Medicaid Services (CMS) on January 1, 2018. Recently, CMS announced that the 2023 Medicare outpatient payment rates will be restored to rates prior to 2018 for affected hospitals. After many legal debates, court filings, and outcry from hospitals […]
In June, the Supreme Court gave hospitals participating in the 340B Drug Pricing Program a convincing victory ruling unanimously that the U.S. Center for Medicare & Medicaid Services (CMS) should not have reduced reimbursement for covered outpatient prescription drugs purchased by those hospitals. 340B Hospitals Challenge Payment Rates Hospitals challenged the 2018 and 2019 payment […]
Great news for 340B Hospitals affected by COVID-19. On March 15, 2022, President Biden signed into law the $1.5 trillion Consolidated Appropriations Acts, 2022. This bill allows Hospitals that have lost eligibility due to a decrease in their Medicare disproportionate share (DSH) percentage as a result of the COVID-19 public health emergency to regain access […]
The 340B Program has seen a lot of changes in 2021. Join Blue & Co.’s Apexus Advanced 340B Experts for a webinar on Thursday, July 15 at 12:00 p.m. In this webinar, Jason Prokopik and Chad Downing will be covering some of the current 340B trends and provide updates from recent HRSA Audits that may […]
After months of pharmaceutical manufacturers placing restrictions on the 340B Program to both contract pharmacies and covered entities, HRSA sent letters to six pharmaceutical manufacturers stating they violated the 340B Statute. The HRSA Acting Administrator declared these pharmaceutical manufacturers violated the 340B statue by placing restrictions on the 340B Program pricing at both contract pharmacy […]